The Institute of Urology and Human Reproductive Health at Sechenov University has been granted a patent for an innovative treatment method for prostate enlargement that preserves normal ejaculation and reproductive function.
The Institute of Urology and Human Reproductive Health at Sechenov University has announced that it has received a patent for an innovative method of treating prostate enlargement that allows for the preservation of normal ejaculation and reproductive function, as well as reducing the risk of developing stress incontinence after surgery.
A statement issued by the university's press office said that the institute has become the first medical institution in Russia to obtain a patent for this treatment technique, noting that its main advantages lie in preserving normal ejaculation and reproductive capacity in patients.
The method developed by the university specialists relies on the use of a 22-channel miniature surgical device within the minimally invasive laser ablation (MiLEP) technique, along with a thulium fiber laser. The technique also involves the early removal of the apex of the benign prostatic tumor while preserving a portion of the enlarged tissue 1.5 centimeters from the seminal vesicle. This helps minimize urethral injury and reduces the likelihood of postoperative stress incontinence.
Vladislav Petov, a urologist and researcher at the institute, said the technique was tested on 15 patients, with results showing that normal ejaculation was preserved in 60% of participants, a percentage consistent with global results recorded in standard ejaculation-preserving resections.
He added that urologists intend to continue developing and improving this technique, noting that studies are currently underway to compare the ejaculation-preserving MiLEP technique with other minimally invasive surgical methods used to treat benign prostatic hyperplasia.
